



Registration and light Lunch

1200

2025 APPHON/ROHPPA Conference IWK – 5850/5980 University Ave, Halifax NS / Virtual via MS Teams

AGENDA

DAY ONE Thursday, May 1st

1300	Welcome and Introductions
1305	Hem/Onc Case Review – Dr. Lisa Goodyear
1335	Discussion / Q&A
1345	Chronic Transfusion Therapy – Jill Mitchell & Chantale Deyoung
1420	Discussion / Q&A
1430	Break
1445	Iron in the community – Dr. Lisa Pinto
1520	Discussion / Q&A
1530	Adjourn
	DAY TWO
	Friday, May 2 nd
0800	Registration and Coffee
0830	Welcome
0845	Cardio Oncology – Mary Stuart
0908	Discussion / Q&A
0915	When a child or parent says 'no' to treatment – Amanda Porter
0950	Discussion / Q&A
1000	Break
1015	SSPedi: Symptom Screening in Pediatrics Tool – Dr. Lillian Sung, Guest Speaker
1105	Discussion / Q&A
1115	Precision Medicine in Pediatric Oncology: Expanding the Playing Field, or a Whole New Game? – Dr. Chelsea Ash
1150	Discussion / Q&A
1200	AGM – Carol Digout
1215	Lunch
1300	Hodgkin's Lymphoma Update – Dr. Ketan Kulkarni
1335	Discussion / Q&A
1345	Provincial Meetings (break served in rooms)
1515	COG updates: Spring 2025 – Dr. Craig Erker
1550	Discussion / Q&A
1600	Adjourn



DAY THREE Saturday, May 3rd

0830	Coffee
0900	Welcome
0915	Blinatumomab, part 1 – Marjorie McGibbon, Misty Spencer, and Tonette Despres
0938	Discussion / Q&A
0945	Blinatumomab, part 2 – Dr. Joanne Delaney
1008	Discussion / Q&A
1015	Discipline specific meetings (break served in rooms)
1130	Oncofertility – Sarah Keeping and Toni Leamon
1153	Discussion / Q&A
1200	Lunch
1245	Pediatric Oncology Palliative Care in Atlantic Canada: A Needs Assessment – Erin Thorne
1308	Discussion / Q&A
1315	The financial impact of pediatric cancer treatment to families treated at the IWK – Zara Forbrigger
1338	Discussion / Q&A
1345	Leukemia and Lymphoma Society of Canada – Brooke Dewhurst
1356	Discussion / Q&A
1400	Guidelines Update – Dr. Tamara MacDonald
1335	Discussion / Q&A
1445	Adiourn

Learning Objective for the Conference

After attending this conference, participants will discover new guidelines, practices, literature, and treatment of patients with hematologic/oncologic diseases.



Educationally approved by Dalhousie University Continuing Professional Development and Medical Education.

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Dalhousie University Continuing Professional Development and Medical Education. You may claim a maximum of 13.0 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at: edhub.ama-assn.org/pages/applications.

In keeping with CMA Guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs of the course and not to individual speakers through an unrestricted educational grant.



CONTINUING PROFESSIONAL DEVELOPMENT & MEDICAL EDUCATION

Funding Sponsors

This program has received an educational grant / sponsorship or in-kind support from:







